Completed
CTN 205: Valproic acid and HIV
Use of valproic acid to purge HIV from resting CD4+ memory cells: Trial results
Learn MoreCompleted
Use of valproic acid to purge HIV from resting CD4+ memory cells: Trial results
Learn MoreCompleted
A Phase I/II safety and immunogencity study of a combination of whole-killed HIV-1 antigen and Amplivax, administered with or without IFA, in HIV-1 infected Participants: Trial results
Learn MoreCompleted
A pilot study to determine the impact of therapeutic HIV vaccination followed by a scheduled interruption of antiretroviral therapy on HIV-specific immune function and virologic rebound in patients with prolonged viral suppression: Trial results
Learn MoreCompleted
A Prospective Randomized Trial of Structured Treatment Interruption (STI) Followed by the Initiation of a New Antiretroviral Regimen vs. Immediate Switching to a New Antiretroviral Regimen in HIV-Infected Patients Experiencing Virologic Failure on HAART
Learn MoreCompleted
An International, Open-Label, Randomized, Multicentre Study to Evaluate the Antiviral Effect, Tolerability, Safety and Pharmacokinetics of Fortovase (saquinavir SGC) and Norvir (ritonavir) QD vs. Crixivan (indinavir) and Norvir (ritonavir) BID in HIV-Infected Patients
Learn MoreCompleted
An Open-Label, Comparative Study to Evaluate the Antiviral Efficacy and Safety of Nevirapine and Efavirenz or Both Drugs Combined in Combination with d4T and 3TC. (The 2NN or Double Non-Nucleoside Study): Trial results
Learn MoreCompleted
Phase I Safety and Immunogenicity Study of CpG ODN 7909 as an Immune Modulator and Adjuvant to Engerix®-B Vaccine in Haart-Treated, HIV-Positive Patients: Trial results
Learn MoreCompleted
Open-Label, Randomized, Multicenter Study to Evaluate Fortovase® (Saquinavir SGC) QD, Norvir® (Ritonavir) QD plus Two NRTIs Vs. SustivaTM (Efavirenz) QD plus Two NRTIs in HIV-Infected Patients: Trial results
Learn MoreReporting
Camu Camu effects on circulating LPS and systemic immune activation in ART-treated participants
Learn MoreCTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.